1,588
Views
0
CrossRef citations to date
0
Altmetric
Outstanding Awards Brief Reports

11th International Congress on Psychopharmacology & 7th International Symposium on Child and Adolescent Psychopharmacology

References

  • Бохан HA. Нейробиологические проблемы изучения аддиктивных расстройств. Сибирский вестник психиатрии и наркологии 2008; 1:59-63.
  • Abdullaeva VK. Clinical-psychological and pathochemical mechanisms of the opioid addiction of persons with comorbid pathology. ISJ Theoretical & Applied Science 2016; 01(33): 58-63.
  • Khalsa JH. Medical Consequences of Drug Abuse and Cooccurring Infections: Research at the National Institute on Drug Abuse. Subst. Abus 2008; 29 (3):5-16.
  • Brent D, Mann JJ. Family genetic studies, suicide, and suicidal behavior. Am J Med Genet Part C Semin Med Genet. 2005 Feb 15;133C(1):13–24.
  • Stieg MR, Sievers C, Farr O, Stalla GK, Mantzoros CS. Leptin: A hormone linking activation of neuroendocrine axes with neuropathology. Psychoneuroendocrinology. 2015;51:47–57.
  • Milaneschi Y, Simmons WK, van Rossum EFC, Penninx BW. Depression and obesity: evidence of shared biological mechanisms. Mol Psychiatry. 2018 Feb 16
  • Hryhorczuk C, Sharma S, Fulton SE. Metabolic disturbances connecting obesity and depression. Front Neurosci. 2013;7(7 OCT):1–14.
  • Sambrook J, Fritsch E, Maniatis T. Molecular Cloning: A Laboratory Manual (Fourth Edition). 2nd ed. New York, USA: Cold-Spring Harbor; 1989. 9.16-9.19.
  • Gotoda T, Manning BS, Goldstone AP, Imrie H, Evans AL, Strosberg AD, et al. Leptin receptor gene variation and obesity: lack of association in a white British male population. Hum Mol Genet. 1997 Jun;6(6):869–76.
  • Jakopec M. Association between LEPR gene 1019 polymorphism and the morphological characteristics in Roma population of Croatia. Master Thesis. 2015.
  • Suriyaprom K, Tungtrongchitr R, Thawnasom K. Measurement of the levels of leptin, BDNF associated with polymorphisms LEP G2548A, LEPR Gln223Arg and BDNF Val66Met in Thai with metabolic syndrome. Diabetol Metab Syndr. 2014;6(1):6.
  • Atmaca M, Kuloglu M, Tezcan E, Ustundag B, Gecici O, Firidin B. Serum leptin and cholesterol values in suicide attempters. Neuropsychobiology. 2002;45(3):124–7.
  • Tutuncu R, Gunay H, Balibey H, Abaslı D. Decreased Leptin Levels in Antisocial Personality Disorder Patients. Klin Psikofarmakol Bülteni-Bulletin Clin Psychopharmacol. 2013 Mar 8;23(1):72–6.
  • Fattore L, Fratta W. Beyond THC: The New Generation of Cannabinoid Designer Drugs. Front Behav Neuroscience. 2011;5(September):1–12.
  • Cohen K, Kapitány-Fövény M, Mama Y, Arieli M, Rosca P, Demetrovics ZWA. The effects of synthetic cannabinoids on executive function. 2017; 1121-1134.
  • Yilmaz H, Bozkurt M, Evren C, Umut G, Keskinkilic C. Evaluation of cognitive functions in individuals with synthetic cannabinoid use disorder and comparison to individuals with cannabis use disorder. Psychiatry Res. 2018;262(June 2017):46–54.
  • Ornstein TJ, Iddon JL, Baldacchino AM, Sahakian BJ, London M, Everitt BJ, et al. Profiles of cognitive dysfunction in chronic amphetamine and heroin abusers. Neuropsychopharmacology. 2000;23(2):113–126.
  • Pau CWH, Lee TMC, Chan SFF. The impact of heroin on frontal executive functions. Arch Clin Neuropsychol. 2002;17(7):663–670.
  • Karakaş S, Erdoğan E, Sak L, Soysal AŞ. Stroop Testi TBAG Formu: Türk Kültürüne Standardizasyon Çalışmaları. Klin Psikiyatr. 1999;75–88.
  • Karakaş S. (WCST) ve Stroop Testi TBAG formu puanlarının test içi ve testler-arası ilişkileri. X Ulus Psikol Kongresi özet kitabı. 1998;44.
  • Won E, Kim Y-K. Stress the autonomic nervous system, and the immune-kynurenine pathway in the etiology of depression. Current neuropharmacology. 2016;14(7):665-73.
  • Hochstrasser T, Ullrich T, Sperner-Unterweger B, Humpel C. Inflammatory stimuli reduce survival of serotonergic neurons and induce neuronal expression of indoleamine 2,3-dioxygenase in rat dorsal raphe nucleus organotypic brain slices. Neuroscience. 2011;184: 128-38.
  • Chen Y, Guillemin GJ. Kynurenine pathway metabolites in humans: disease and healthy states. International Journal of Tryptophan Research. 2009; 2: IJTR. S2097.
  • Hallmayer J, Cleveland S, Torres A, Phillips J, Cohen B, Torigoe T, et al. Genetic heritability and shared environmental factors among twin pairs with autism. Archives of general psychiatry. 2011;68(11):1095-102.
  • Caglayan AO. Genetic causes of syndromic and non-syndromic autism. Developmental Medicine & Child Neurology. 2010;52(2):130-8.
  • Geschwind DH. Genetics of autism spectrum disorders. Trends in cognitive sciences. 2011;15(9):409-16.
  • Huguet G, Benabou M, Bourgeron T. The Genetics of Autism Spectrum Disorders. In: Sassone-Corsi P, Christen Y, editors. A Time for Metabolism and Hormones. Cham: Springer International Publishing; 2016. p. 101-29.
  • Anney R, Klei L, Pinto D, Regan R, Conroy J, Magalhaes TR, et al. A genome-wide scan for common alleles affecting risk for autism. Human molecular genetics. 2010;19(20):4072-82.
  • Chen D, Vollmar M, Rossi MN, Phillips C, Kraehenbuehl R, Slade D, et al. Identification of macrodomain proteins as novel O-acetyl-ADP-ribose deacetylases. The Journal of biological chemistry. 2011;286(15):13261-71.
  • Han W, Li X, Fu X. The macro domain protein family: structure, functions, and their potential therapeutic implications. Mutation research. 2011;727(3):86-103.
  • Tsang KM, Croen LA, Torres AR, Kharrazi M, Delorenze GN, Windham GC, et al. A genome-wide survey of transgenerational genetic effects in autism. PloS one. 2013;8(10):e76978.
  • Curran S, Bolton P, Rozsnyai K, Chiocchetti A, Klauck SM, Duketis E, et al. No association between a common single nucleotide polymorphism, rs4141463, in the MACROD2 gene and autism spectrum disorder. American journal of medical genetics Part B, Neuropsychiatric genetics: the official publication of the International Society of Psychiatric Genetics. 2011;156b(6):633-9.
  • Anney R, Klei L, Pinto D, Almeida J, Bacchelli E, Baird G, et al. Individual common variants exert weak effects on the risk for autism spectrum disorders. Human molecular genetics. 2012;21(21):4781-92.
  • Prandini P, Pasquali A, Malerba G, Marostica A, Zusi C, Xumerle L, et al. The association of rs4307059 and rs35678 markers with autism spectrum disorders is replicated in Italian families. Psychiatric genetics. 2012;22(4):177-81.
  • Jones RM, Cadby G, Blangero J, Abraham LJ, Whitehouse AJO, Moses EK. MACROD2 gene associated with autistic-like traits in a general population sample. Psychiatric genetics. 2014;24(6):241-8.
  • Kuo PH, Chuang LC, Su MH, Chen CH, Chen CH, Wu JY, et al. Genome-Wide Association Study for Autism Spectrum Disorder in Taiwanese Han Population. PloS one. 2015;10(9):e0138695.
  • Namjou B, Marsolo K, Caroll RJ, Denny JC, Ritchie MD, Verma SS, et al. Phenome-wide association study (PheWAS) in EMR-linked pediatric cohorts, genetically links PLCL1 to speech language development and IL5-IL13 to Eosinophilic Esophagitis. Frontiers in genetics. 2014;5:401.
  • Torrico B, Chiocchetti AG, Bacchelli E, Trabetti E, Hervas A, Franke B, et al. Lack of replication of previous autism spectrum disorder GWAS hits in European populations. Autism research: official journal of the International Society for Autism Research. 2017;10(2):202-11.
  • Consortium AG. Meta-analysis of GWAS of over 16,000 individuals with autism spectrum disorder highlights a novel locus at 10q24.32 and a significant overlap with schizophrenia. Molecular autism. 2017;8:21.
  • Piven J, Elison JT, Zylka MJ. Toward a conceptual framework for early brain and behavior development in autism. Molecular Psychiatry. 2017;23:165.
  • Schopler E, Reichler RJ, DeVellis RF, Daly K. Toward objective classification of childhood autism: Childhood Autism Rating Scale (CARS). Journal of autism and developmental disorders. 1980;10(1):91-103.
  • İncekaş S, Baykara B, Avcil S, Demiral Y. Validity and Reliability Analysis of Turkish Version of Childhood Autism Rating Scale. Turkish Journal of Psychiatry. 2016;27(4).
  • Sucuoğlu B. The psychometric characteristics of the Turkish form of the aberrant behavior checklist. Turk Psikol Derg. 2003;18:77-9.
  • Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nature Protocols. 2008;3:1101.
  • Kang HJ, Kawasawa YI, Cheng F, Zhu Y, Xu X, Li M, et al. Spatio-temporal transcriptome of the human brain. Nature. 2011;478(7370):483-9.
  • Ansel A, Rosenzweig JP, Zisman PD, Melamed M, Gesundheit B. Variation in Gene Expression in Autism Spectrum Disorders: An Extensive Review of Transcriptomic Studies. Frontiers in Neuroscience. 2016;10:601.
  • Kessler, RC, et al., Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Archives of General Psychiatry, 2005. 62(6): p. 593-602.
  • Kessler, RC. The costs of depression. Psychiatric Clinics, 2012. 35(1): p. 1-14.
  • Türkçapar, H. Bilişsel terapi: Temel ilkeler ve uygulama. 2009: HYB Yayıncılık, 2002 (Medico Graphics Ofset).
  • Hoyt, B. D. (2005). Sleep in patients with neurologic and psychiatric disorders. Primary care, 32(2), 535-48.
  • Wilson, S., & Argyropoulos, S. (2012). Sleep in schizophrenia: time for closer attention. The British Journal of Psychiatry, 200(4), 273-274.
  • YETKİN, S., & AYDIN, H. (2014). Psikotropik İlaçların Uyku Üzerine Etkileri. Turkiye Klinikleri Journal of Psychiatry Special Topics, 7(1), 36-42.
  • Miller, D. D. (2004). Atypical antipsychotics: sleep, sedation, and efficacy. Primary care companion to the Journal of clinical psychiatry, 6(suppl 2), 3.
  • Yamashita H, Morinobu S, and Yamawaki S. et al. Effect of risperidone on sleep in schizophrenia: a comparison with haloperidol. Psychiatry Res. 2002 109:137–142. [PubMed]
  • Collaborative Working Group on Clinical Trial Evaluations. Measuring outcome in schizophrenia: differences among the atypical antipsychotics. J Clin Psychiatry. 1998 59suppl 12. 3–9.
  • Idzikowski C, Mills FJ, Glennard R. 5-Hydroxytryptamine-2 antagonist increases human slow wave sleep. Brain Res. 1986;378:164–168
  • Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment followingacute relapse of schizophrenia. Int J Neuropsychopharmacol 2003; 6 (4): 325-37.
  • Monti, J. M., Torterolo, P., & Perumal, S. R. P. (2017). The effects of second generation antipsychotic drugs on sleep variables in healthy subjects and patients with schizophrenia. Sleep medicine reviews, 33, 51-57.
  • Xiang Y, Weng Y, Li W et al. Training patients with schizophrenia with the community re-entry module: a controlled study. Soc Psychiatry Psychiatr Epidemiol 2006; 41:464-469.
  • Foruzandeh, N., & Parvin, N. (2013). Occupational therapy for inpatients with chronic schizophrenia: a pilot randomized controlled trial. Japan Journal of Nursing Science, 10(1), 136-141.
  • Perilli, V., Stasolla, F., Maselli, S., & Morelli, I. (2018). Occupational Therapy and Social Skills Training for Enhancing Constructive Engagement of Patients with Schizophrenia: A Review.
  • Karatay G, Kubilay G. Sosyoekonomik düzeyi farklı iki lisede madde kullanma durumu ve etkileyen faktörlerin belirlenmesi. Hemşirelikte Araştırma Geliştirme Dergisi, 1(2), 57-70, 2004.
  • Karakaş SA, Ersöğütçü F. Madde Bağımlılığı ve Hemşirelik. Sağlık Bilimleri ve Meslekleri Dergisi, 3(2), 133-139, 2016.
  • European Monitoring Centre for Drugs and Drug Addiction. (2018). European Drug Report: Trends and Developments, 2018.
  • Tamar-Gurol D, Sar V, Karadag F, Evren C, Karagoz M. Childhood emotional abuse, dissociation, and suicidality among patients with drug dependency in Turkey. Psychiatry and Clinical Neurosciences, 62(5), 540-547, 2008.
  • Bilici R, Beker ŞD, Süner Ö, Çıtak S, Izci F. Sociodemographic characteristics of Turkish patients who violated a supervised probation program. Journal of ethnicity in substance abuse, 17(3), 335-344, 2018.
  • Şıpka H, Sönmez B, Karaca E, Vardar E. Bir üniversite hastanesi bağımlılık merkezinde yatarak tedavi gören hastaların profili: Bir yıllık AMATEM verilerinin incelenmesi. 50. Ulusal Psikiyatri Kongresi. Turk Psikiyatri Derg, 25, 32; 2014.
  • Bulut M, Savaş HA, Cansel N, Selek S, Kap Ö, Yumru M, Vırıt O. Gaziantep Üniversitesi Alkol Ve Madde Kullanim Bozukluklari Birimine Başvuran Hastalarin Sosyodemografik Özellikleri. Journal of Dependence, 7, 65-70; 2006.
  • Çakmak D, Kralı A, Akvandaz Y. Son beş yıl içinde AMATEM’e yatan bağımlıların özellikleri. 1996.
  • Alpay N, Maner F, Kalyoncu A. AMATEM’de 1990 yılında yatırılan madde bağımlılarının demografik özellikleri ve geçmiş yıllarla kıyaslanması. 27. Ulusal Psikiyatri Kongresi Program ve Bildiri Özetleri Kitabı, 177. 1991
  • Türkiye Uyuşturucu ve Uyuşturucu Bağımlılığı İzleme Merkezi. Türkiye Uyuşturucu Raporu. Ankara: Yazar. 2018.
  • Galea S, Vlahov D. Social determinants and the health of drug users: socioeconomic status, homelessness, and incarceration. Public health reports, 117(Suppl 1), S135. 2002.
  • Sherba RT, Coxe KA, Gersper BE, Linley JV. Employment services and substance abuse treatment. Journal of substance abuse treatment, 87, 70-78; 2018.
  • Arria AM, Topps-II Interstate Cooperative Study Group. Drug treatment completion and post-discharge employment in the TOPPS-II interstate cooperative study. Journal of Substance Abuse Treatment, 25(1), 9–18. 2003.
  • Vaillant GE. What can long-term follow-up teach us about relapse and prevention of relapse in addiction? British Journal of Addiction, 83(10), 1147–1157. 1988.
  • Ritter A, Cameron J. A review of the efficacy and effectiveness of harm reduction strategies for alcohol, tobacco and illicit drugs. Drug and Alcohol Review, 25(6), 611–624. 2006.
  • Harrison PA, Asche SE. Outcomes monitoring in Minnesota: treatment implications, practical limitations. Journal of Substance Abuse Treatment, 21(4), 173-183. 2001.
  • Manuel JI, Yuan Y, Herman DB, Svikis DS, Nichols O, Palmer E, Deren S. Barriers and facilitators to successful transition from long-term residential substance abuse treatment. Journal of Substance Abuse Treatment, 74, 16–22. 2017
  • Ahern J, Stuber J, Galea S. (2007). Stigma, discrimination and the health of illicit drug users. Drug and Alcohol Dependence, 88(2-3), 188–196. 2007.
  • Ertüzün E, Uyaroğlu AK, Demirel B, Koçak E. Boş Zaman Aktivitelerinin Madde Bağımlılığı Sürecindeki Rolüne İlişkin Nitel Bir Çalışma. Spor Bilimleri Dergisi, 27(2), 49-58. 2016.
  • Gundogmus, İ., Algul, A., Karagöz, A. and Kıyançiçek, M. PDW and RDW are new parameters for bipolar episodes and unipolar depression. Psychiatry and Clinical Psychopharmacology 2018;4: 1-7.
  • Erzin, G., Kotan, V.O., Topçuoğlu, C., Özkaya, G., Erel, Ö., Yüksel, R.N., Ürer, E., Aydemir, M.Ç. and Göka, E. Thiol/disulphide homeostasis in bipolar disorder. Psychiatry research 2018;261: 237-242.
  • Usta, M.B., Karabekiroglu, K., Sahin, B., Aydin, M., Bozkurt, A., Karaosman, T., Aral, A., Cobanoglu, C., Kurt, A.D., Kesim, N. and Sahin, İ., 2018. Use of machine learning methods in prediction of short-term outcome in autism spectrum disorders. Psychiatry and Clinical Psychopharmacology 2018;16:1-6.
  • Soygür H. Psikofarmakolojinin Tarihsel Gelişimi. Yüksel N, editor. Temel Psikofarmakoloji. Ankara: Türkiye Psikiyatri Derneği Yayınları; 2010. s: 1–15.
  • Glennon J, Purper-Ouakil D, Bakker M, et al. Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challenges. Eur Child Adolesc Psychiatry. 2014;23(12):1149–1160. Published online 2013 Dec 15.
  • Arabgol F, Panaghi L, Nikzad V. Risperidone versus Methylphenidate in Treatment of Preschool Children With Attention-Deficit Hyperactivity Disorder. Iran J Pediatr. 2015 Feb;25(1):e265. Published online 2015 Feb 21.
  • Garfield LD, Brown DS, Allaire BT, Ross RE, Nicol GE, Raghavan R. Psychotropic Drug Use Among Preschool Children in the Medicaid Program From 36 States. Am J Public Health. 2015 March;105(3):524–529. Published online 2015 March. doi: 10.2105/AJPH.2014.302258
  • Johnston AN, Bu W, Hein S, Garcia S, Camacho L, Xue L, et al. Hyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions. Breast Cancer Res. 2018;20:42. Published online 2018 May 19.
  • Corkum P, Tannock R, Moldofsky H. Sleep disturbances in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1998;37:637–646.
  • Miano S, Parisi P, Villa MP. The sleep phenotypes of attention deficit hyperactivity disorder: The role of arousal during sleep and implications for treatment. Medical Hypotheses 2012;79:147–153.
  • Weiss MD, Salpekar J. Sleep problems in the child with attention-deficit hyperactivity disorder. CNS drugs. 2010;24(10):811–828.
  • Corbetta M, Patel G, Shulman GL. The reorienting system of the human brain: from environment to theory of mind. Neuron 2008;58(3):306–324.
  • Eklund A, Nichols TE, Knutsson H. Cluster failure: why fMRI inferences for spatial extent have inflated false-positive rates. Proc Natl Acad Sci U S A 2016;113(28):7900–7905.
  • Kim BN, Lee JS, Shin MS, Cho SC, Lee DS. Regional cerebral perfusion abnormalities in attention deficit/hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci 2002;252(5):219–225.
  • Lee JS, Kim BN, Kang E, Lee DS, Kim YK, Chung JK, Lee MC, Cho SC. Regional cerebral blood flow in children with attention deficit hyperactivity disorder: comparison before and after methylphenidate treatment. Human Brain Mapp. 2005;24(3):157–164.
  • O’Gorman RL, Mehta MA, Asherson P, Zelaya FO, Brookes KJ, Toone BK, Alsop DC, Williams SC. Increased cerebral perfusion in adult attention deficit hyperactivity disorder is normalised by stimulant treatment: a non-invasive MRI pilot study. Neuroimage 2008;42(1):36–41.
  • Uzbay TI. Pharmacological importance of agmatine in brain. Neurosci Biobehav Rev. 2012; 36:502–519.
  • Uzbay T. A new target for diagnosis and treatment of CNS disorders: Agmatinergic system. Curr Med Chem. 2012b;19:5116–5121.
  • Reis DJ, Regunathan S. Agmatine: an endogenous ligand at imidazoline receptors may be a novel neurotransmitter in brain. J Auton Nerv Syst. 1998;72:80–85.
  • Madai VI, Poller WC, Peters D, et al. Synaptic localisation of agmatinase in rat cerebral cortex revealed by virtual pre-embedding. Amino Acids. 2012;43:1399–1403.
  • Halaris A, Plietz J. Agmatine. CNS drugs. 2007;21:885–900.
  • Auguet M, Viossat I, Marin JG, Chabrier PE. Selective inhibition of inducible nitric oxide synthase by agmatine. Jpn J Pharmacol. 1995;69:285–287.
  • Feng Y, LeBlanc MH, Regunathan S. Agmatine reduces extracellular glutamate during pentylenetetrazole-induced seizures in rat brain: a potential mechanism for the anticonvulsive effects. Neurosci Lett. 2005;390:129–133.
  • Galea E, Regunathan S, Eliopoulos V, Feinstein DL. Inhibition of mammalian nitric oxide synthases by agmatine, an endogenous polyamine formed by decarboxylation of arginine. Biochem J. 1996;316:247–249.
  • Wang WP, Iyo AH, Miguel-Hidalgo J, Regunathan S, Zhu MY. Agmatine protects against cell damage induced by NMDA and glutamate in cultured hippocampal neurons. Brain Res. 2006;1084:210–216.
  • Wang XF, Wu N, Su RB, Lu XQ, Liu Y, Li J. Agmatine modulates neuroadaptations of glutamate transmission in the nucleus accumbens of repeated morphine-treated rats. Eur J Pharmacol. 2011;650:200–205.
  • Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991;148:1301–1308.
  • Treen D, Batlle S, Mollà L, et al. Are there glutamate abnormalities in subjects at high risk mental state for psychosis? A review of the evidence. Schizophren Res. 2016;171:166–175.
  • Weinberger DR, McClure RK. Neurotoxicity, neuroplasticity, and magnetic resonance imaging morphometry: what is happening in the schizophrenic brain? Arch Gen Psychiatry. 2002;59:553–558.
  • Yao JK, Leonard S, Reddy RD. Increased nitric oxide radicals in postmortem brain from patients with schizophrenia. Schizophren Bull. 2004;30:923–934.
  • Yao JK, Reddy R. Oxidative stress in schizophrenia: pathogenetic and therapeutic implications. Antioxid Redox Signal. 2001;15:1999–2002.
  • Shim S, Shuman M, Duncan E. An emerging role of cGMP in the treatment of schizophrenia: a review. Schizophren Res. 2016;170:226–231.
  • Garthwaite J. Glutamate, nitric oxide and cell-cell signalling in the nervous system. Trends Neurosci. 1991;14:60–67.
  • Uzbay IT, Oglesby MW. Nitric oxide and substance dependence. Neurosci Biobehav Rev. 2001;25:43–52.
  • Hallak JE, Maia-de-Oliveira JP, Abrao J, et al. Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: a randomized, double-blind, placebo-controlled trial. JAMA Psychiatry. 2013;70:668–676.
  • Liu P, Jing Y, Collie ND, Dean B, Bilkey DK, Zhang H. Altered brain arginine metabolism in schizophrenia. Transl Psychiatry. 2016;6:e871.
  • Uzbay T, Kayir H, Goktalay G, Yildirim M. Agmatine disrupts prepulse inhibition of acoustic startle reflex in rats. J Psychopharmacol. 2010;24:923–929.
  • Kotagale NR, Taksande BG, Wadhwani PJ, et al. Psychopharmacological study of agmatine in behavioral tests of schizophrenia in rodents. Pharmacol Biochem Behav. 2012;100:398–403.
  • Pålsson E, Fejgin K, Wass C, Klamer D. Agmatine attenuates the disruptive effects of phencyclidine on prepulse inhibition. Europ J Pharmacol. 2008;590:212–216.
  • Uzbay T, Goktalay G, Kayir H, et al. Increased plasma agmatine levels in patients with schizophrenia. J Psychiatric Res. 2013;47:1054–1060.
  • American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington (DC): American Psychiatric Association; 2013.
  • Yang KC, Reis DJ. Agmatine selectively blocks the N-methyl-D-aspartate subclass of glutamate receptor channels in rat hippocampal neurons. J Pharmacol Exp Ther. 2004;288:544–549.
  • Tsai G, Coyle JT. Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol. 2002;42:165–791.
  • Lindsley CW, Shipe WD, Wolkenberg SE, et al. Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia. Curr Top Med Chem. 2006;6:771–785.
  • Harrison PJ. Metabotropic glutamate receptor agonists for schizophrenia. Br J Psychiatry. 2008;192:86–87.
  • Knox LT, Jing Y, Collie ND, Zhang H, Liu P. Effects of acute phencyclidine administration on arginine metabolism in the hippocampus and prefrontal cortex in rats. Neuropharmacol. 2014;81:195–205.
  • Djordjević VV, Stojanović I, Stanković-Ferlež D, et al. Plasma nitrite/nitrate concentrations in patients with schizophrenia. Clin Chem Lab Med. 2010;48:89–94.
  • Yilmaz N, Herken H, Cicek HK, Celik A, Yürekli M, Akyol Ö. Increased levels of nitric oxide, cortisol and adrenomedullin in patients with chronic schizophrenia. Med Princip Practic. 2007;16:137–141.
  • Baba H, Suzuki T, Arai H, Emson PC. Expression of nNOS and soluble guanylate cyclase in schizophrenic brain. Neuroreport 2004;15:677–680.
  • Lauer M, Johannes S, Fritzen S, Senitz D, Riederer P, Reif A. Morphological abnormalities in nitric-oxide-synthase-positive striatal interneurons of schizophrenic patients. Neuropsychobiol. 2005;52:111–117.
  • Gupta N, Jing Y, Collie ND, Zhang H, Liu P. Ageing alters behavioural function and brain arginine metabolism in male Sprague–Dawley rats. Neuroscience. 2012;226:178–196.
  • Rushaidhi M, Jing Y, Kennard JT, et al. Aging affects l-arginine and its metabolites in memory-associated brain structures at the tissue and synaptoneurosome levels. Neurosci. 2012;209:21–31.
  • Liu P, Zhang H, Devaraj R, Ganesalingam GS, Smith PF. A multivariate analysis of the effects of aging on glutamate, GABA and arginine metabolites in the rat vestibular nucleus. Hearing Res. 2010;269:122–133.
  • Liu P, Chary S, Devaraj R, et al. Effects of aging on agmatine levels in memory-associated brain structures. Hippocampus. 2008;18:853–856.
  • Esnafoglu E, Irende I. Decreased plasma agmatine levels in autistic subjects. J Neural Transmiss. 2018;125:735–740.
  • Chen GG, Almeida D, Fiori L, Turecki G. Evidence of reduced agmatine concentrations in the cerebral cortex of suicides. Int J Neuropsychopharmacol. 2018; doi: 10.1093/ijnp/pyy058
  • Maia-de-Oliveira JP, Lobão-Soares B, Ramalho T, et al. Nitroprusside single-dose prevents the psychosis-like behavior induced by ketamine in rats for up to one week. Schizophr Res. 2015;162:211–215.
  • Deutsch SI, Rosse RB, Schwartz BL, Fay-McCarthy M, Rosenberg PB, Fearing K. Methylene blue adjuvant therapy of schizophrenia. Clin Neuropharmacol. 1997;20:357–363.
  • Goodwin RD, et al., Epidemiology of Mood Disorders. 2006.
  • Simon GE, et al., An international study of the relation between somatic symptoms and depression. N Engl J Med. 1999;341(18):1329–1335.
  • Terre L, et al., Do somatic complaints predict subsequent symptoms of depression? Psychother Psychosom. 2003;72(5):261–267.
  • Pennebaker JW. Emotion, disclosure, and health: An overview. 1995.
  • Hirokawa K, Yagi A, Miyata Y. An examination of the effects of stress management training for Japanese college students of social work. Int J Stress Manag. 2002;9(2):113–123.
  • American Psychiatric Association. Attention-deficit/hyperactivity disorder. In: Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington (VA): American Psychiatric Association; 2013. p. 59.
  • DuPaul GJ, Stoner G. ADHD in the Schools. Assessment and Intervention Strategies. New York: Guilford Press; 2003.
  • Uzbay İT. Bağımlılık yapan maddeler ve özellikleri. MİSED (Türk Eczacıları Birliği Meslek İçi Sürekli Eğitim Dergisi). 2009;Aralık(21-22):16–33.
  • Türkcan A. Alkolün Biyolojik Etkileri, Farmakolojisi, Emilimi, Dağılımı, Metabolizması ve Organ Sistemleri Üzerine Etkileri. Turkiye Klinikleri J Psychiatry Special Top. 2010;3(3):30–36.
  • İT U. Alkol, Farmakolojik özellikleri ve alkol bağımlılığının nörofarmakolojik yönü. Ege Psikiyatri Sürekli Yayınları (Alkol kullanım bozuklukları ve tedavisi). 1996;1(2):227–254.
  • Türkyılmaz M, Özsüt H. Direnci Azalmış Konaklarda Görülen İnfeksiyonlar:Alkol Bağımlılarında Görülen İnfeksiyonlar ve Ateş. Klimik Dergisi. 2018;31:145–148.
  • Kilic E, Rezvani A, Toprak AE, Erman H, Ayhan SK, Poyraz E, et al. Evaluation of neutrophil to lymphocyte and platelet to lymphocyte ratios in rheumatoid arthritis. Dicle Med J. 2016;43(2):241–247.
  • Yilmaz A, Can Y, Bozkurt M, Evren C. Alkol ve Madde Bagimliliginda Remisyon ve Depresme/Remission and Relapse in Alcohol and Substance Addiction. Psikiyatride Guncel Yaklasimlar. 2014;6(3):243.
  • Guzel D, Yazici AB, Yazici E, Erol A. Alterations of the hematologic cells in synthetic cannabinoid users. J Clin Lab Anal. 2017;31(6):e22131.
  • Guzel D, Yazici AB, Yazici E, Erol A. Evaluation of Immunomodulatory and Hematologic Cell Outcome in Heroin/Opioid Addicts. J Addict. 2018;2018:2036145. PubMed PMID: 30631635.
  • Jesse S, Brathen G, Ferrara M, Keindl M, Ben-Menachem E, Tanasescu R, et al. Alcohol withdrawal syndrome: mechanisms, manifestations, and management. Acta Neurol Scand. 2017 Jan;135(1):4–16. PubMed PMID: 27586815. Pubmed Central PMCID: PMC6084325. Epub 2016/09/03. eng.
  • Becker HC. Alcohol dependence, withdrawal, and relapse. Alcohol Res Health J Natl Inst Alcohol Abuse Alcohol. 2008;31(4):348–361. PubMed PMID: 23584009.
  • Antonopoulos, CN, Kadoglou, NP, 2016. Biomarkers in silent traumatic brain injury. Curr Pharm Des. 22, 680-7.
  • Al-Ayadhi, LY, Mostafa, GA., 2012. A lack of association between elevated serum levels of S100B protein and autoimmunity in autistic children. J Neuroinflammation. 16, 9-54.
  • Nelson, PG., Kuddo, T, Song, EY, Dambrosia, JM, Kohler, S, Satyanarayana, G, Vandunk, C, Grether, JK, Nelson, KB, 2006. Selected neurotrophins, neuropeptides, and cytokines: developmental trajectory and concentrations in neonatal blood of children with autism or Down syndrome. Int J Dev Neurosci. 24,73-80.
  • Mabunga DF, Gonzales EL, Kim JW, Kim KC, Shin CY. Exploring the Validity of Valproic Acid Animal Model of Autism. Exp Neurobiol 2015;24(4):285-300.
  • Crawley JN. Mouse behavioral assays relevant to the symptoms of autism. Brain Pathol 2007;17(4):448-59.
  • Wink LK, Adams R, Horn PS, Tessier CR, Bantel AP, Hong M, et al. A Randomized Placebo-Controlled Cross-Over Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorder. J Autism Dev Disord 2018;48(9):3051-3060.